Patient characteristics, treatment patterns, and mortality in elderly patients newly diagnosed with acute myeloid leukemia meeting ineligibility criteria for high intensity chemotherapy

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA A Cancer J Clin. 2020;70(1):7–30.
   PubMed Web of Science ®Google Scholar
• Shallis RM, Wang R, Davidoff A, et al. Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges. Blood Rev. 2019;36:70–87.
   PubMed Web of Science ®Google Scholar
• Turbeville S, Francis KM, Behm I, et al. Prevalence and incidence of acute myeloid leukemia may be higher than currently accepted estimates among the ≥65 year-old population in the United States. Blood. 2014;124(21):958–958.
   Google Scholar
• Hao T, Li-Talley M, Buck A, et al. An emerging trend of rapid increase of leukemia but not all cancers in the aging population in the United States. Sci Rep. 2019;9(1):12070.
   PubMed Web of Science ®Google Scholar
• Tallman MS, Wang ES, Altman JK, et al. Acute myeloid leukemia, version 3.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2019;17(6):721–749.
   PubMed Web of Science ®Google Scholar
• Cerrano M, Itzykson R. New treatment options for acute myeloid leukemia in 2019. Curr Oncol Rep. 2019;21(2):16.
   PubMed Web of Science ®Google Scholar
• Zehir A, Benayed R, Shah RH, et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat Med. 2017;23(6):703–713.
   PubMed Web of Science ®Google Scholar
• Webster JA, Pratz KW. Acute myeloid leukemia in the elderly: therapeutic options and choice. Leuk Lymphoma. 2018;59(2):274–287.
   PubMed Web of Science ®Google Scholar
• Tomlinson BK, Gallogly MM, Kane DM, et al. A phase II study of midostaurin and 5-azacitidine for untreated elderly and unfit patients with FLT3 wild-type acute myelogenous leukemia. Clin Lymphoma Myeloma Leuk. 2020;20(4):226–233.
   PubMedGoogle Scholar
• DiNardo CD, Pratz K, Pullarkat V, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2019;133(1):7–17.
   PubMed Web of Science ®Google Scholar
• Mues KE, Liede A, Liu J, et al. Use of the medicare database in epidemiologic and health services research: a valuable source of real-world evidence on the older and disabled populations in the US. Clin Epidemiol. 2017;9:267–277.
   PubMed Web of Science ®Google Scholar
• Craig BM, Rollison DE, List AF, et al. Underreporting of myeloid malignancies by United States cancer registries. Cancer Epidemiol Biomarkers Prev. 2012;21(3):474–481.
   PubMedGoogle Scholar
• Irish W, Ryan M, Gache L, et al. Acute myeloid leukemia: a retrospective claims analysis of resource utilization and expenditures for newly diagnosed patients from first-line induction to remission and relapse. Curr Med Res Opin. 2017;33(3):519–527.
   PubMed Web of Science ®Google Scholar
• Davidoff AJ, Zuckerman IH, Pandya N, et al. A novel approach to improve health status measurement in observational claims-based studies of cancer treatment and outcomes. J Geriatr Oncol. 2013;4(2):157–165.
   PubMed Web of Science ®Google Scholar
• Li S, Natwick T, Liu J, et al. Mortality by a proxy performance status as defined by a claims-based measure for disability status in older patients with newly diagnosed multiple myeloma in the United States. J Geriatr Oncol. 2019;10(3):490–496.
   PubMedGoogle Scholar
• Davidoff AJ, Gardner LD, Zuckerman IH, et al. Validation of disability status, a claims-based measure of functional status for cancer treatment and outcomes studies. Med Care. 2014;52(6):500–510.
   PubMed Web of Science ®Google Scholar
• Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43(11):1130–1139.
   PubMed Web of Science ®Google Scholar
• Quan H, Li B, Couris CM, et al. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol. 2011;173(6):676–682.
   PubMed Web of Science ®Google Scholar
• Medeiros BC, Satram-Hoang S, Hurst D, et al. Big data analysis of treatment patterns and outcomes among elderly acute myeloid leukemia patients in the United States. Ann Hematol. 2015;94(7):1127–1138.
   PubMed Web of Science ®Google Scholar
• Bories P, Bertoli S, Bérard E, et al. Intensive chemotherapy, azacitidine, or supportive care in older acute myeloid leukemia patients: an analysis from a regional healthcare network. Am J Hematol. 2014;89(12):E244–252.
   PubMed Web of Science ®Google Scholar
• Ma E, Bonthapally V, Chawla A, et al. An evaluation of treatment patterns and outcomes in elderly patients newly diagnosed with acute myeloid leukemia: a retrospective analysis of electronic medical records from US community oncology practices. Clin Lymphoma Myeloma Leuk. 2016;16(11):625–636.e623.
   PubMed Web of Science ®Google Scholar
• Bhatt VR, Chen B, Gyawali B, et al. Socioeconomic and health system factors associated with lower utilization of hematopoietic cell transplantation in older patients with acute myeloid leukemia. Bone Marrow Transplant. 2018;53(10):1288–1294.
   PubMed Web of Science ®Google Scholar
• Lipof JJ, Loh KP, O'Dwyer K, et al. Allogeneic hematopoietic cell transplantation for older adults with acute myeloid leukemia. Cancers. 2018;10(6):179
   PubMedGoogle Scholar
• Pidala J, Craig BM, Lee SJ, et al. Practice variation in physician referral for allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2013;48(1):63–67.
   PubMedGoogle Scholar
• Kalin B, Pijnappel EN, van Gelder M, et al. Intensive treatment and trial participation in elderly acute myeloid leukemia patients: a population-based analysis in the Netherlands. Cancer Epidemiol. 2018;57:90–96.
   PubMedGoogle Scholar
• Ho G, Jonas BA, Li Q, et al. Early mortality and complications in hospitalized adult Californians with acute myeloid leukaemia. Br J Haematol. 2017;177(5):791–799.
   PubMed Web of Science ®Google Scholar
• Estey EH. Acute myeloid leukemia: 2019 update on risk-stratification and management. Am J Hematol. 2018;93(10):1267–1291.
   PubMed Web of Science ®Google Scholar
• Venclexta (venetoclax). Full prescribing information., AbbVie Inc., North Chicago, IL, 2020.
   Google Scholar
• DiNardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383(7):617–629.
   PubMed Web of Science ®Google Scholar
• Wei AH, Strickland SA, Jr., Hou JZ, et al. Venetoclax combined with low-dose cytarabine for previously untreated patients with acute myeloid leukemia: results from a phase Ib/II study. J Clin Oncol. 2019;37(15):1277–1284.
   PubMed Web of Science ®Google Scholar
• Winters AC, Gutman JA, Purev E, et al. Real-world experience of venetoclax with azacitidine for untreated patients with acute myeloid leukemia. Blood Adv. 2019;3(20):2911–2919.
   PubMed Web of Science ®Google Scholar
• Percival ME, Lai C, Estey E, et al. Bone marrow evaluation for diagnosis and monitoring of acute myeloid leukemia. Blood Rev. 2017;31(4):185–192.
   PubMed Web of Science ®Google Scholar